<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="8749cf61-2e35-473a-bfe5-49d342a17ff3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ENDOMETRIN safely and effectively.<br/>
      <br/>See full prescribing information for ENDOMETRIN.<br/>
      <br/>
      <br/>
      <br/>ENDOMETRIN <sup>Â®</sup> (progesterone)<br/>
      <br/>Vaginal Insert 100 mg<br/>
      <br/>Initial U.S. Approval: 2007</title>
   <effectiveTime value="20250327"/>
   <setId root="2ba50fa9-b349-40cb-9a4b-1af8faa4ec09"/>
   <versionNumber value="21"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="103722955"/>
            <name>Ferring Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="508638848"/>
                        <name>QPharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="55566-6500" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="55566-6500" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="878265586"/>
                        <name>Pharmaceutics International Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="55566-6500" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="618054084"/>
                        <name>Pharmacia and Upjohn Company LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="55566-6500" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="86e8c45a-bf0d-43a7-98d0-838848790ec6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250131"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55566-6500" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ENDOMETRIN</name>
                        <formCode code="C60933" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INSERT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Progesterone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="76A0JE0FKJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ADIPIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BICARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROGESTERONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55566-6500-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="21" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="55566-6500-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="55566-6500-3" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20070621"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022057" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070621"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>Oblong</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">FPI;100</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38313" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VAGINAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="21766a48-1fa0-4e60-8fd6-ff730cd20c41"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ENDOMETRIN<sup>Â®</sup> (progesterone) is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ENDOMETRIN<sup>Â®</sup> is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. (<linkHtml href="#s1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="10648d4b-ba51-4c63-9925-03905940a07e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The dose of ENDOMETRIN is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to  10 weeks total duration. Efficacy in women 35 years of age and older has not been clearly established. The appropriate dose of ENDOMETRIN in this age group has not been determined. (<linkHtml href="#s2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2.1">
                     <id root="8953ca31-f830-4b7d-a447-8e1d8d771b0a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	General Dosing Information</title>
                     <text>
                        <paragraph>The dose of ENDOMETRIN is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration. Efficacy in women 35 years of age and older has not been clearly established. The appropriate dose of ENDOMETRIN in this age group has not been determined.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="180d0108-3c66-4276-8019-19e693afa8bb"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>100 mg vaginal insert is a white to off-white oblong-shaped tablet debossed with "FPI" on one side and "100" on the other side.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>100 mg vaginal insert (<linkHtml href="#s3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4c7079f9-1139-4d27-9cef-148530edd5cd"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ENDOMETRIN is contraindicated in individuals with any of the following conditions:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN [<content styleCode="italics">see <linkHtml href="#s11">Description (11)</linkHtml>
                        </content>]</item>
                     <item>Undiagnosed vaginal bleeding</item>
                     <item>Known missed abortion or ectopic pregnancy</item>
                     <item>Liver disease</item>
                     <item>Known or suspected malignancy of the breast or genital organs</item>
                     <item>Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events</item>
                  </list>
               </text>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN Vaginal Insert (<linkHtml href="#s4">4</linkHtml>)</item>
                           <item>Undiagnosed vaginal bleeding (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Known missed abortion or ectopic pregnancy (<linkHtml href="#s4">4</linkHtml>)</item>
                           <item>Liver disease (<linkHtml href="#s4">4</linkHtml>)</item>
                           <item>Known or suspected malignancy of the breast or genital organs (<linkHtml href="#s4">4</linkHtml>)</item>
                           <item>Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events (<linkHtml href="#s4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="06f1c36c-ca93-4077-825f-c84edf4ede86"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. Discontinue ENDOMETRIN if any of these are suspected. (<linkHtml href="#s5.1">5.1</linkHtml>)</item>
                           <item>Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen. (<linkHtml href="#s5.2">5.2</linkHtml>)</item>
                           <item>ENDOMETRIN is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert. (<linkHtml href="#s5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5.1">
                     <id root="4f666cf3-c4e9-48d6-bf04-06f38d641bc7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Cardiovascular or Cerebrovascular Disorders</title>
                     <text>
                        <paragraph>The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.2">
                     <id root="0b0eda94-b085-4cc9-a5e0-492c75e19207"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Depression</title>
                     <text>
                        <paragraph>Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.3">
                     <id root="b9a8de3e-e4d5-42c4-9819-f0b941c62d55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Use of Other Vaginal Products</title>
                     <text>
                        <paragraph>ENDOMETRIN should not be recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert [<content styleCode="italics">see <linkHtml href="#s7">Drug Interactions (7)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="4a5eae3d-7d18-420c-a0f8-80ea3cffb98a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions reported (greater than 2%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome. (<linkHtml href="#s6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">This leaflet summarizes the most important information about ENDOMETRIN. To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                        <paragraph>Â </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6.1">
                     <id root="0ed7e867-b80f-481e-9dd1-12567c4568f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety data reflect exposure to ENDOMETRIN in 808 infertile women (74.9% White, 10.3% Hispanic, 5.4% Black, 5% Asian, and 4.6% Other) in a single Assisted Reproductive Technology 10 week clinical study conducted in the U.S. ENDOMETRIN was studied at doses of 100 mg twice daily and 100 mg three times daily. The adverse reactions that occurred at a rate greater than or equal to 2% in either ENDOMETRIN group are summarized in Table 1.</paragraph>
                        <table width="100%" ID="table1">
                           <caption>Table 1: Number and Frequency of Reported Adverse Reactions in Women Treated with ENDOMETRIN in an Assisted Reproductive Technology Study</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule">Body System</th>
                                 <th rowspan="2" styleCode="Rrule">ENDOMETRIN<br/>100 mg twice daily<br/>(N=404)</th>
                                 <th rowspan="2" styleCode="Rrule">ENDOMETRIN<br/>100 mg three times daily<br/>(N=404)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">Â Â Preferred Term</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Abdominal pain</td>
                                 <td styleCode="Rrule">50 (12%)</td>
                                 <td styleCode="Rrule">50 (12%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Nausea</td>
                                 <td styleCode="Rrule">32 (8%)</td>
                                 <td styleCode="Rrule">29 (7%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Abdominal distension</td>
                                 <td styleCode="Rrule">18 (4%)</td>
                                 <td styleCode="Rrule">17 (4%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Constipation</td>
                                 <td styleCode="Rrule">9 (2%)</td>
                                 <td styleCode="Rrule">14 (3%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Vomiting</td>
                                 <td styleCode="Rrule">13 (3%)</td>
                                 <td styleCode="Rrule">9 (2%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Fatigue</td>
                                 <td styleCode="Rrule">7 (2%)</td>
                                 <td styleCode="Rrule">12 (3%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Infections and Infestations</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Urinary tract infection</td>
                                 <td styleCode="Rrule">9 (2%)</td>
                                 <td styleCode="Rrule">4 (1%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Injury, Poisoning and Procedural Complications</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Post-oocyte retrieval pain</td>
                                 <td styleCode="Rrule">115 (28%)</td>
                                 <td styleCode="Rrule">102 (25%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Headache</td>
                                 <td styleCode="Rrule">15 (4%)</td>
                                 <td styleCode="Rrule">13 (3%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Reproductive System and Breast Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Ovarian hyperstimulation syndrome</td>
                                 <td styleCode="Rrule">30 (7%)</td>
                                 <td styleCode="Rrule">27 (7%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Uterine spasm</td>
                                 <td styleCode="Rrule">15 (4%)</td>
                                 <td styleCode="Rrule">11 (3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Vaginal bleeding</td>
                                 <td styleCode="Rrule">13 (3%)</td>
                                 <td styleCode="Rrule">14 (3%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other less common reported adverse reactions included vaginal irritation, itching, burning, discomfort, urticaria, and peripheral edema.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="s6.2">
                     <id root="1dc0255a-a541-4149-aace-222996d092c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Expected Adverse Reaction Profile Seen with Progesterone</title>
                     <text>
                        <paragraph>ENDOMETRIN is also expected to have adverse reactions similar to other drugs containing progesterone that may include breast tenderness, bloating, mood swings, irritability, and drowsiness.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="9fbe93ba-01d8-4240-acf8-f2a2aaf509b9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>No formal drug-drug interaction studies have been conducted for ENDOMETRIN. Drugs known to induce the hepatic cytochrome-P450-3A4 system (such as rifampin, carbamazepine) may increase the elimination of progesterone.</paragraph>
                  <paragraph>The effect of concomitant vaginal products on the exposure of progesterone from ENDOMETRIN has not been assessed. ENDOMETRIN is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert [<content styleCode="italics">see <linkHtml href="#s5.3">Warnings and Precautions (5.3)</linkHtml>
                     </content>].</paragraph>
               </text>
               <effectiveTime value="20250131"/>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="c65b7e23-3533-4599-9ad2-e28f874173a8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S8.1">
                     <id root="c2d754df-0be3-4d31-93ff-f45dc5b3d66a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>ENDOMETRIN has been used to support embryo implantation and maintain clinical pregnancy in one clinical study. The live birth outcomes of these pregnancies were as follows:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Among the 404 subjects treated with ENDOMETRIN twice daily, 143 subjects had live births consisting of 85 singletons, 56 twins, and 2 triplets. In this treatment group, 13 subjects had a spontaneous abortion, 1 subject had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.4% based on 203 livebirths).</item>
                           <item>Among the 404 subjects treated with ENDOMETRIN three times daily, 155 subjects had livebirths consisting of 91 singletons, 60 twins, and 4 triplets. In this treatment group, 22 subjects had a spontaneous abortion, 4 subjects had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.1% based on 223 livebirths).</item>
                        </list>
                        <paragraph>Birth defects reported in the ENDOMETRIN twice daily group included: one fetus with a cleft palate and intrauterine growth retardation, one fetus with spina bifida, three fetuses with congenital heart defects, one fetus with an umbilical hernia, and one fetus with an intestinal anomaly.</paragraph>
                        <paragraph>Birth defects reported in the ENDOMETRIN three times daily group included: one fetus with an esophageal fistula, one fetus with hypospadias and an underdeveloped right ear, one fetus with Down Syndrome and an atrial septal defect, one fetus with congenital heart anomalies, one fetus with DiGeorge's syndrome, one fetus with a hand deformity, and one fetus with cleft palate.</paragraph>
                        <paragraph>For additional information on the pharmacology of ENDOMETRIN and pregnancy outcome information [ <content styleCode="italics">see <linkHtml href="#s12">Clinical Pharmacology (12)</linkHtml> and <linkHtml href="#s14">Clinical Studies Sections (14)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="c677dcc8-9b8a-4875-be1e-fe1f9f49a977"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3	Nursing Mothers</title>
                     <text>
                        <paragraph>Detectable amounts of progesterone have been identified in the milk of nursing mothers. The effect of this on the nursing infant has not been determined.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="2483afe1-5f52-4c26-893e-a2c178b2522e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>This drug is not intended for pediatric use and no clinical data have been collected in children. Therefore, the safety and effectiveness of ENDOMETRIN in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="13a881eb-5c9f-4c3b-9b8a-444c747ac51c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>No clinical data have been collected in patients over age 65.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="0ae724fa-1447-4236-9061-45f635922592"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Treatment of overdosage consists of discontinuation of ENDOMETRIN together with institution of appropriate symptomatic and supportive care.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="cf8c7f54-cbb4-4086-bec7-e84712a531b2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ENDOMETRIN (progesterone) Vaginal Insert contains micronized progesterone. ENDOMETRIN is supplied with polyethylene vaginal applicators.</paragraph>
                  <paragraph>The active ingredient, progesterone, is present in 100 mg amount along with other excipients. The chemical name for progesterone is pregn-4-ene-3,20-dione. It has an empirical formula of C<sub>21</sub>H<sub>30</sub>O<sub>2</sub> and a molecular weight of 314.5. Progesterone exists in two polymorphic forms. The form used in ENDOMETRIN, the alpha-form, has a melting point of 127-131Â°C.</paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Each ENDOMETRIN Vaginal Insert delivers 100 mg of progesterone in a base containing lactose monohydrate, polyvinylpyrrolidone, adipic acid, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate, pregelatinized starch, and colloidal silicon dioxide.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="endometrin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="c4a03dcb-812c-4700-98f3-d96e742dd6a3"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S12.1">
                     <id root="f7f236c0-1dab-4ba1-97d9-c7fa151ed659"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="08201dc1-4dc7-4e5f-a93e-eff9bd041a1b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	 Pharmacokinetics</title>
                     <effectiveTime value="20250131"/>
                     <component>
                        <section>
                           <id root="90be4bc4-ef8f-4244-afd9-2ff87d2aa679"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Absorption</content>
                              </paragraph>
                              <paragraph>Progesterone serum concentrations increased following the administration of the ENDOMETRIN Vaginal Insert in 12 healthy pre-menopausal females. On single dosing, the mean C<sub>max</sub> was 17.0 ng/mL in the ENDOMETRIN twice daily group and 19.8 ng/mL in the ENDOMETRIN three times daily group. On multiple dosing, steady-state concentrations were attained within approximately 1 day after initiation of treatment with ENDOMETRIN. Both ENDOMETRIN regimens provided average serum concentrations of progesterone exceeding 10 ng/mL on Day 5. The pharmacokinetic results are summarized in Table 2.</paragraph>
                              <table width="100%" ID="table2">
                                 <caption>Table 2: Mean (Â±Standard Deviation) Serum Progesterone Pharmacokinetic Parameters</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th align="center" styleCode="Lrule Rrule">Pharmacokinetic Parameter (unit)</th>
                                       <th styleCode="Rrule">ENDOMETRIN 100 mg<br/>twice daily (N=6)</th>
                                       <th styleCode="Rrule">ENDOMETRIN 100 mg<br/>three times daily (N=6)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="3" valign="top">C<sub>max</sub> Maximum progesterone serum concentration.</td>
                                    </tr>
                                    <tr>
                                       <td align="left" colspan="3" valign="top">T<sub>max</sub> Time to maximum progesterone serum concentration.</td>
                                    </tr>
                                    <tr>
                                       <td align="left" colspan="3" valign="top">C<sub>avg</sub> Average progesterone serum concentration.</td>
                                    </tr>
                                    <tr>
                                       <td align="left" colspan="3" valign="top">AUC<sub>0-24</sub> Area under the drug concentration versus time curve from 0-24 hours post dose.</td>
                                    </tr>
                                    <tr>
                                       <td align="left" colspan="3" valign="top">C<sub>min</sub> Minimum progesterone serum concentration.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="center" colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Single Dosing</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>max</sub> (ng/mL)</td>
                                       <td styleCode="Rrule">17.0 Â± 6.5</td>
                                       <td styleCode="Rrule">19.8 Â± 7.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">T<sub>max</sub> (hr)</td>
                                       <td styleCode="Rrule">24.0 Â± 0.0</td>
                                       <td styleCode="Rrule">17.3 Â± 7.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AUC<sub>0-24</sub>
                                          <br/>(ngâhr/mL)</td>
                                       <td styleCode="Rrule">217 Â± 113</td>
                                       <td styleCode="Rrule">284 Â± 143</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Day 5 of Multiple Dosing</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>max</sub> (ng/mL)</td>
                                       <td styleCode="Rrule">18.5 Â± 5.5</td>
                                       <td styleCode="Rrule">24.1 Â± 5.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">T<sub>max</sub> (hr)</td>
                                       <td styleCode="Rrule">18.0 Â± 9.4</td>
                                       <td styleCode="Rrule">18.0 Â± 9.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>min</sub> (ng/mL)</td>
                                       <td styleCode="Rrule">8.9 Â± 4.5</td>
                                       <td styleCode="Rrule">10.9 Â± 6.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>avg</sub> (ng/ml)</td>
                                       <td styleCode="Rrule">14.0 Â± 4.8</td>
                                       <td styleCode="Rrule">15.9 Â± 4.3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">AUC<sub>0-24</sub>
                                          <br/>(ngâhr/mL)</td>
                                       <td styleCode="Rrule">327 Â± 127</td>
                                       <td styleCode="Rrule">436 Â± 106</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4e9ebda9-c4cf-4858-8d06-501c4c2b070f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Distribution</content>
                              </paragraph>
                              <paragraph>Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin.</paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0a054287-d5f6-49dc-b15d-b910b3ec845d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>Progesterone is metabolized primarily by the liver, largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization.</paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="05bbbfe8-4b36-4a7a-b797-18ae6d783f0c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>Progesterone undergoes renal and biliary elimination. Following injection of labeled progesterone, 50-60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and feces. Overall recovery of the labeled material accounts for 70% of an administered dose. Only a small portion of unchanged progesterone is excreted in the bile<content styleCode="italics">.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="167c98f4-bf89-463b-b37f-e0f1c9368c70"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S13.1">
                     <id root="07fca9b0-9622-499f-a20f-df8c33c8f3ba"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Nonclinical toxicity studies to determine the potential of ENDOMETRIN to cause carcinogenicity or mutagenicity have not been performed. The effect of ENDOMETRIN on fertility has not been evaluated in animals.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="c7dfbc8b-3d63-4e4c-bdcc-a8857d776a9e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="s14.1">
                     <id root="0e59a154-8237-41ff-8d59-ba977abadb71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Luteal Supplementation During Assisted Reproductive Treatment Study</title>
                     <text>
                        <paragraph>A randomized, open-label, active-controlled study evaluated the efficacy of 10 weeks of treatment with two different daily dosing regimens of ENDOMETRIN (100 mg twice daily and 100 mg three times daily) for support of implantation and early pregnancy in infertile women participating in an Assisted Reproductive Technology treatment program. Efficacy was assessed on the endpoint of ongoing pregnancies, defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer. The study randomized to ENDOMETRIN 808 infertile women (74.9% White; 10.3% Hispanic, 5.4% Black, 5% Asian, and 4.6% Other) between 19 and 42 years of age (mean age 33) who had a body mass index &lt;34 kg/m<sup>2</sup> at screening.</paragraph>
                        <paragraph>The ongoing pregnancy rates for subjects treated with both dosing regimens of ENDOMETRIN were non-inferior (lower bounds of the 95% confidence interval of the difference between ENDOMETRIN and the active comparator excluded a difference greater than 10%) to the ongoing pregnancy rate for subjects treated with the active comparator. The results of this study are shown in Table 3.</paragraph>
                        <table width="100%" ID="table3">
                           <caption>Table 3: Ongoing Pregnancy Rates<footnote ID="K1547">Ongoing pregnancy defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer.</footnote> in Patients Receiving ENDOMETRIN for Luteal Supplementation and Early Pregnancy While in an Assisted Reproductive Technology Treatment Program</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="23%" align="center" valign="top"/>
                           <col width="27%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">ENDOMETRIN<br/>100 mg twice daily</th>
                                 <th styleCode="Rrule">ENDOMETRIN<br/>100 mg three times daily</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Number of subjects</td>
                                 <td styleCode="Rrule">404</td>
                                 <td styleCode="Rrule">404</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Ongoing pregnancy: n (%)</td>
                                 <td styleCode="Rrule">156 (39%)</td>
                                 <td styleCode="Rrule">171 (42%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% Confidence Interval of pregnancy rate</td>
                                 <td styleCode="Rrule">[33.8, 43.6]</td>
                                 <td styleCode="Rrule">[37.5, 47.3]</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Pregnancy rate percentage difference between ENDOMETRIN and comparator</td>
                                 <td styleCode="Rrule">-3.6%</td>
                                 <td styleCode="Rrule">0.1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">95% Confidence Interval for difference vs comparator</td>
                                 <td styleCode="Rrule">[-10.3, 3.2]</td>
                                 <td styleCode="Rrule">[-6.7, 6.9]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Subjects participating in the study were stratified at randomization by age and ovarian reserve (as measured by serum FSH levels). The ongoing pregnancy rates for these subgroups are shown in Table 4.</paragraph>
                        <table width="100%" ID="table4">
                           <caption>Table 4: Ongoing Pregnancy Rates in Age- and Ovarian Reserve-Defined Subgroups Receiving ENDOMETRIN for Luteal Supplementation and Early Pregnancy While in an Assisted Reproductive Technology Treatment Program</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="23%" align="center" valign="top"/>
                           <col width="27%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">ENDOMETRIN<br/>100 mg twice daily</th>
                                 <th styleCode="Rrule">ENDOMETRIN<br/>100 mg three times daily</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule">Subjects age &lt; 35 years (N)</td>
                                 <td styleCode="Rrule">247</td>
                                 <td styleCode="Rrule">247</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Ongoing pregnancy: n (%)</td>
                                 <td styleCode="Rrule">111 (45%)</td>
                                 <td styleCode="Rrule">117 (47%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Pregnancy rate percentage difference between ENDOMETRIN and comparator</td>
                                 <td styleCode="Rrule">0.5%</td>
                                 <td styleCode="Rrule">2.9%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% Confidence Interval for difference vs. comparator</td>
                                 <td styleCode="Rrule">[-8.3, 9.3]</td>
                                 <td styleCode="Rrule">[-5.9, 11.7]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Subjects 35-42 years of age (N)</td>
                                 <td styleCode="Rrule">157</td>
                                 <td styleCode="Rrule">157</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Ongoing pregnancy: n (%)</td>
                                 <td styleCode="Rrule">45 (28%)</td>
                                 <td styleCode="Rrule">54 (34%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Pregnancy rate percentage difference between ENDOMETRIN and comparator</td>
                                 <td styleCode="Rrule">-10.1%</td>
                                 <td styleCode="Rrule">-4.4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% Confidence Interval for difference vs. comparator</td>
                                 <td styleCode="Rrule">[-20.3, 0.3]</td>
                                 <td styleCode="Rrule">[-14.9, 6.3]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Subjects with FSH &lt; 10 IU/L (N)</td>
                                 <td styleCode="Rrule">350</td>
                                 <td styleCode="Rrule">347</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Ongoing pregnancy: n (%)</td>
                                 <td styleCode="Rrule">140 (40%)</td>
                                 <td styleCode="Rrule">150 (43%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Pregnancy rate percentage difference between ENDOMETRIN and comparator</td>
                                 <td styleCode="Rrule">-2.0%</td>
                                 <td styleCode="Rrule">1.2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% Confidence Interval for difference vs. comparator</td>
                                 <td styleCode="Rrule">[-9.3, 5.3]</td>
                                 <td styleCode="Rrule">[-6.1, 8.5]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Subjects with FSH between 10 and 15 IU/L (N) </td>
                                 <td styleCode="Rrule">46</td>
                                 <td styleCode="Rrule">51</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Ongoing pregnancy: n (%)</td>
                                 <td styleCode="Rrule">16 (35%)</td>
                                 <td styleCode="Rrule">20 (39%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Pregnancy rate percentage difference between ENDOMETRIN and comparator</td>
                                 <td styleCode="Rrule">-12.2%</td>
                                 <td styleCode="Rrule">-7.7%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">95% Confidence Interval for difference vs. comparator</td>
                                 <td styleCode="Rrule">[-31.0, 7.7]</td>
                                 <td styleCode="Rrule">[-26.6, 11.6]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In subjects under the age of 35 or with serum FSH levels less than 10 IU/L, results from both dosing regimens were non-inferior to the results from the comparator with respect to ongoing pregnancy rates. In women age 35 and older and in women with serum FSH levels between 10 and 15 IU/L, the results with respect to ongoing pregnancy rates for both dosing regimens of ENDOMETRIN did not reach the criteria for non-inferiority.</paragraph>
                        <paragraph>Subjects who became pregnant received study medication for a total of 10 weeks. Patients over 34 kg/m<sup>2</sup> were not studied. The efficacy of ENDOMETRIN in this patient group is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="49d13b57-9071-4e9f-b3cb-7671eb0c8caa"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Each ENDOMETRIN Vaginal Insert is a white to off-white oblong-shaped insert debossed with "FPI" on one side and "100" on the other side. Each ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, is packed individually in a sealed foil pouch. These pouches are available in cartons packed:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>21 vaginal inserts with 21 disposable vaginal applicators (NDC 55566-6500-3)</item>
                  </list>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="id_link_6bee64c5-a36e-e744-e053-2991aa0a4190">
                     <id root="8509a9c2-bc44-4fc4-ac1c-ae88d4afb265"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 20 - 25Â°C (68 - 77Â°F); excursions permitted between 15 - 30Â°C (59 - 86Â°F).</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="69ac9c80-8210-44b8-a780-032acb2af82a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>See FDA-Approved Patient Labeling.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="s17.1">
                     <id root="dc2d8d4e-adc7-4cb5-a77d-e9439cfb041b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1	Vaginal Bleeding</title>
                     <text>
                        <paragraph>Inform patients of the importance of reporting irregular vaginal bleeding to their doctor as soon as possible.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="s17.2">
                     <id root="67a401d0-580f-48d5-937c-4ee525ebf9e2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2	Common Adverse Reactions with Progesterone</title>
                     <text>
                        <paragraph>Inform patients of the possible side effects of progesterone therapy such as headaches, breast tenderness, bloating, mood swings, irritability, and drowsiness.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="s17.3">
                     <id root="38f43e9e-f2c4-4f99-adca-e3336ce38cd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3	Coadministration of Other Vaginal Products</title>
                     <text>
                        <paragraph>Inform patients that ENDOMETRIN is not recommended for use with other vaginal products.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36af04d4-050d-4718-b1eb-f32ebade261e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>MANUFACTURED FOR:<br/>FERRING PHARMACEUTICALS INC.<br/>PARSIPPANY, NJ 07054</paragraph>
                  <paragraph>XXXXXXXXXX<br/>Revised: 1/2025</paragraph>
               </text>
               <effectiveTime value="20250131"/>
            </section>
         </component>
         <component>
            <section ID="id_link_6bee64c5-a371-e744-e053-2991aa0a4190">
               <id root="88e1c3d9-2352-40dc-a6ba-2cb743be4629"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="100%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" align="center">PATIENT INFORMATION <br/>ENDOMETRIN (en-doh-ME-trin)<br/>(progesterone)<br/>for vaginal insert</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">IMPORTANT: <content styleCode="underline">For Vaginal Use Only</content>. </content>
                              <br/>Read the patient information that comes with ENDOMETRIN <sup>Â®</sup> (progesterone) before you start to use it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. Your doctor may do a physical exam before prescribing ENDOMETRIN.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">What is ENDOMETRIN?</content>
                              <br/>ENDOMETRIN is a vaginal insert that contains the hormone progesterone. ENDOMETRIN is for women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) program.<br/>Progesterone is one of the hormones essential for helping you to become and to stay pregnant. If you are undergoing ART treatment, your doctor may prescribe ENDOMETRIN to provide the progesterone your body needs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Who should not use ENDOMETRIN?</content>
                              <br/>Do not use ENDOMETRIN if you: 									<list listType="unordered" styleCode="Disc">
                                 <item>Are allergic to anything in ENDOMETRIN. See the end of this leaflet for a complete list of ingredients.</item>
                                 <item>Have unusual vaginal bleeding that has not been evaluated by a doctor.</item>
                                 <item>Currently have or have had liver problems or cancer of the breast or genital organs.</item>
                                 <item>Have or have had blood clots in the legs, lungs, eyes, or elsewhere in your body.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">ENDOMETRIN may not be right for you. Before starting ENDOMETRIN, tell your doctor about all your health problems</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vaginal products, vitamins, and herbal supplements.</content>
                              </paragraph>
                              <paragraph>Some medicines may affect ENDOMETRIN.</paragraph>
                              <paragraph>Know what medicines you take. Keep a list of your medicines to show to the doctor and pharmacist.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I use ENDOMETRIN?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use ENDOMETRIN exactly as prescribed. The usual dose of ENDOMETRIN is one insert placed in your vagina 2 to 3 times a day for up to a total of 10 weeks, unless your healthcare provider advises otherwise.</item>
                                 <item>Place an ENDOMETRIN insert in your vagina with the disposable applicator provided.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Follow the steps below:</content>
                              </paragraph>
                              <list listType="ordered" styleCode="arabic">
                                 <item>Unwrap the applicator. Do not use if the contents or packaging are visibly damaged.</item>
                                 <item>Put one insert in the space provided at the end of the applicator. The insert should fit snugly and not fall out.</item>
                                 <item>Place applicator with the insert into the vagina while you are standing, sitting, or when lying on your back with your knees bent. Gently place the thin end of the applicator well into the vagina.</item>
                                 <item>Push the plunger to release the insert.</item>
                                 <item>Remove the applicator and throw it away in the trash.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Other information for using ENDOMETRIN</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you forget a dose of ENDOMETRIN, take the dose as soon as you remember, but do not use more than your daily dose.</item>
                                 <item>Call your doctor if you use too much ENDOMETRIN.</item>
                                 <item>Do not use any other vaginal products when you are using ENDOMETRIN.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of ENDOMETRIN?</content>
                              </paragraph>
                              <paragraph>Common side effects seen with ART and ENDOMETRIN included pelvic pain after surgery, abdominal pain, nausea, and swollen ovaries (ovarian hyperstimulation syndrome).</paragraph>
                              <paragraph>Other reported side effects included abdominal bloating, headache, urinary infections, uterine cramping, constipation, vomiting, tiredness, and vaginal bleeding.</paragraph>
                              <paragraph>Vaginal products with progesterone may also cause vaginal irritation, burning, and discharge.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Serious Risks of Progesterone</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Progesterone can increase your chance of getting blood clots. Blood clots can be serious and lead to death.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Serious blood clots include those in the:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>legs (thrombophlebitis)</item>
                                 <item>lungs (pulmonary embolus)</item>
                                 <item>eyes (blindness)</item>
                                 <item>heart (heart attack)</item>
                                 <item>brain (stroke)</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor or get medical help right away if you have:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>persistent pain in the lower leg (calf)</item>
                                 <item>sudden shortness of breath</item>
                                 <item>coughing up blood</item>
                                 <item>sudden blindness, partial or complete</item>
                                 <item>severe chest pain</item>
                                 <item>sudden, severe headache, vomiting, dizziness, or fainting</item>
                                 <item>weakness in an arm or leg, or trouble speaking</item>
                                 <item>yellowing of the skin and/or white of the eyes indicating possible liver problem</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Other risks of progesterone use include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>headache</item>
                                 <item>breast tenderness</item>
                                 <item>bloating or fluid retention</item>
                                 <item>mood swings and depression</item>
                                 <item>irritability</item>
                                 <item>drowsiness</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor immediately if you have abnormal vaginal bleeding.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">These are not all the side effects with ENDOMETRIN. Ask your doctor or pharmacist for more information.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store ENDOMETRIN?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ENDOMETRIN at room temperature, 20 - 25Â°C (68 - 77Â°F); excursions permitted between 15 - 30Â°C (59 - 86Â°F).</item>
                                 <item>Do not use ENDOMETRIN after the expiration date that is printed on the carton.</item>
                                 <item>Keep ENDOMETRIN and all medicines out of the reach of children.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about ENDOMETRIN</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use ENDOMETRIN for a condition for which it was not prescribed. Do not give ENDOMETRIN to other women, even if they have the same condition as you do. It may harm them.</paragraph>
                              <paragraph>This leaflet summarizes the most important information about ENDOMETRIN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ENDOMETRIN that was written for healthcare professionals. For more information call Ferring Pharmaceuticals Inc. at 1-(888)-FERRING or 1-(888)-337-7464.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in ENDOMETRIN?</content>
                              </paragraph>
                              <paragraph>Active Ingredient: progesterone</paragraph>
                              <paragraph>Inactive Ingredients: lactose monohydrate, polyvinylpyrrolidone, adipic acid, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate, pregelatinized starch, and colloidal silicon dioxide</paragraph>
                              <paragraph>
                                 <content styleCode="bold">MANUFACTURED FOR:</content>
                                 <br/>FERRING PHARMACEUTICALS INC.<br/>
                                 <br/>PARSIPPANY, NJ 07054</paragraph>
                              <paragraph>XXXXXXXXXX<br/>Revised: 1/2025</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250131"/>
            </section>
         </component>
         <component>
            <section ID="PACKAGE_LABEL_OUTER_CARTON">
               <id root="6d807784-3a84-4815-8d6f-b345ed56a19e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Carton</title>
               <text>
                  <paragraph>NDC 55566-6500-3</paragraph>
                  <paragraph>Endometrin<sup>Â®</sup>
                     <br/>(progesterone) Vaginal Insert 100mg</paragraph>
                  <paragraph>Contents:<br/>21 vaginal inserts with 21 disposable vaginal applicators<br/>Each insert contains 100 mg progesterone, USP</paragraph>
                  <paragraph>FOR VAGINAL USE ONLY</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Usual Dosage:<br/>See enclosed package insert for dosage and<br/>complete Prescribing Information.</paragraph>
                  <paragraph>This carton contains instructions intended<br/>for the patient.</paragraph>
                  <paragraph>FERRING<br/>PHARMACEUTICALS</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="endometrin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>